- Home
- CISS vs INM Comparison
CISS vs INM Comparison
Compare CISS & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | INM |
|---|---|---|
| Founded | 2022 | 1981 |
| Country | Greece | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 2.1M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CISS | INM |
|---|---|---|
| Price | $2.08 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 3.0M |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,942,633.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.82 | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $0.08 | $0.58 |
| 52 Week High | $6.06 | $3.34 |
Technical Indicators
Market Signals| Indicator | CISS | INM |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 61.96 |
| Support Level | $2.00 | $1.09 |
| Resistance Level | $2.23 | $1.95 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 38.82 | 21.21 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.